# Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)

> **NCT00771316** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 6 (actual)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **DRUG:** MK0826 (ertapenem)
- **DRUG:** Comparator: meropenem

## Key facts

- **NCT ID:** NCT00771316
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** feasibility and low enrollment
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00771316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00771316, "Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00771316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*